Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine – Delivering Genes
Prioritization on Building External Partnerships and an Internal Pipeline Centered on Gene Therapies and Nucleic Acids
Related news for (MTNB)
- Today’s Top Performers: MoBot’s Market Review 08/15/25 01:00 PM
- Breaking News: MoBot’s Latest Update as of 08/15/25 12:00 PM
- Six Exciting Materials Stocks Heating Up the Market
- 111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.
- Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID